/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

NUVALENT, INC. Share Price Today: Live Updates & Key Insights

NUVALENT, INC. share price today is $98, up -2.05%. The stock opened at $99.12 against the previous close of $100.05, with an intraday high of $99.12 and low of $97.

NUVALENT, INC. Share Price Chart

style
pb-0

NUVALENT, INC.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

NUVALENT, INC. Share Price Performance

$98 -0.0205(-2.05%) NUVL at 13 Mar 2026 02:32 PM Biotechnology
Lowest Today 97
Highest Today 99.12
Today’s Open 99.12
Prev. Close 100.05
52 Week High 113.02
52 Week Low 55.54
Day’s Range: Low 97 High 99.12
52-Week Range: Low 55.54 High 113.02
1 day return -
1 Week return -1.32
1 month return -3.04
3 month return -6.74
6 month return +23.14
1 year return +31.42
3 year return +246.28
5 year return +421.55
10 year return -

NUVALENT, INC. Institutional Holdings

Deerfield Management Co 21.94

FMR Inc 13.80

Paradigm Biocapital Advisors LP 6.70

Vanguard Group Inc 6.67

BlackRock Inc 5.20

JPMorgan Chase & Co 4.26

Wellington Management Company LLP 3.13

Fidelity Growth Compy Commingled Pl S 2.88

HHG PLC 2.78

RA Capital Management, LLC 2.39

T. Rowe Price Associates, Inc. 2.30

Fidelity Growth Company Fund 2.24

Vanguard Total Stock Mkt Idx Inv 2.20

State Street Corp 2.00

Perceptive Advisors LLC 1.99

Vanguard Small Cap Index 1.55

iShares Russell 2000 ETF 1.55

Geode Capital Management, LLC 1.39

Vanguard Health Care Inv 1.34

Bellevue Group AG 1.32

Polar Capital Holdings PLC 1.30

T. Rowe Price Investment Management,Inc. 1.30

Polar Capital Biotech S Inc 1.14

BRAIDWELL LP 1.04

Vanguard Small Cap Value Index Inv 1.00

State Street® SPDR® S&P® Biotech ETF 0.97

Fidelity Select Health Care 0.97

Fairmount Funds Management LLC 0.93

JPMorgan Growth Advantage A 0.91

Adage Capital Partners Gp LLC 0.82

JPM US Mid Cap Growth-Composite 0.78

JPMorgan Mid Cap Growth I 0.78

Woodline Partners LP 0.78

Polar Capital Healthcare Opports Inc 0.76

Vanguard Institutional Extnd Mkt Idx Tr 0.72

Fidelity Small Cap Growth 0.66

T. Rowe Price Health Sciences 0.65

Fidelity Growth Company K6 0.65

Strategic Advisers Fidelity US TtlStk 0.65

US Small-Cap Growth II Equity Comp 0.63

NUVALENT, INC. Market Status

Strong Buy: 8

Buy: 3

Hold: 0

Sell: 0

Strong Sell: 0

NUVALENT, INC. Fundamentals

Market Cap 7865.63 M

PB Ratio 6.3009

PE Ratio 0.0

Enterprise Value 6493.68 M

Total Assets 1412.71 M

Volume 589404

NUVALENT, INC. Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-114050000 -114.1M, FY22:-73346000 -73.3M, FY21:-46338000 -46.3M, FY20:-14556000 -14.6M, FY19:-11809000 -11.8M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:null 0.0M

Quarterly Net worth Q3/2025:-122437000 -122.4M, Q2/2025:-99653000 -99.7M, Q1/2025:-84582000 -84.6M, Q3/2024:-84345000 -84.3M, Q2/2024:-57166000 -57.2M

About NUVALENT, INC. & investment objective

Company Information Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Organisation Biotechnology

Employees 228

Industry Biotechnology

CEO Dr. James R. Porter Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow